©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Integrin -dependent Serine Phosphorylation of Paxillin in Cultured Human Macrophages Adherent to Vitronectin (*)

(Received for publication, December 13, 1995)

Mark O. De Nichilo (§) Kenneth M. Yamada

From the Laboratory of Developmental Biology, NIDR, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The macrophage colony-stimulating factor (M-CSF) is able to induce the expression of the alpha(v)beta(5) integrin receptor on the surface of cultured human macrophages (De Nichilo, M. O., and Burns, G. F.(1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2517-2521). In the present study, we establish that the adhesion of M-CSF-treated macrophages to vitronectin is mediated by the integrin alpha(v)beta(5), and show by indirect immunofluorescence analysis that alpha(v)beta(5) and the cytoskeletal protein paxillin localize to focal contacts upon adhesion to vitronectin. Immunoprecipitation and Western blot analysis revealed that M-CSF-treated macrophages do not express focal adhesion kinase (FAK), thereby providing direct evidence for integrin-dependent localization of paxillin to focal contacts in the absence of FAK expression. Investigation of paxillin phosphorylation by two-dimensional phosphoamino acid analysis indicates that paxillin is 99% phosphorylated on serine residue(s) in response to vitronectin adhesion, and only 1% phosphorylated on tyrosine. Stimulation of protein kinase C (PKC) activity with the phorbol ester phorbol 12-myristate 13-acetate enhances paxillin phosphorylation, while two selective inhibitors of PKC, GF109203X and chelerythrine chloride, effectively block the phosphorylation of paxillin induced in response to vitronectin adhesion. Taken together, these data demonstrate that in M-CSF-treated macrophages adherent to vitronectin, paxillin localizes to focal contacts in the absence of FAK expression and is predominantly phosphorylated on serine residue(s) in a PKC-dependent manner.


INTRODUCTION

Interactions with the extracellular matrix (ECM) (^1)are known to have profound influence on cell growth and differentiation, as well as migration(1) . The receptors that have received most study in this regard belong to a large family of alphabeta heterodimers termed integrins(2) . Integrins function as cell surface receptors for a variety of ECM proteins (including vitronectin, fibronectin, laminin, and the collagens) and are thought to transmit signals to the cell upon ligand occupancy, and thereby regulate cell behavior(3, 4, 5) . The integrin family is now known to consist of over 20 distinct receptors, with the combination of a particular alpha and beta subunit determining ligand specificity(2) . In general, upon binding their specific ligands, the integrins associate with the actin cytoskeleton and organize into structures known as focal contacts (focal adhesions or adhesion plaques)(6) . Focal contacts are thought to act not only as structural links between the ECM and the cytoskeleton, but also as sites of signal transduction from the ECM (6) . Despite their importance, the underlying molecular mechanisms orchestrating the formation of focal contacts upon integrin ligation remain poorly defined.

FAK (focal adhesion kinase) is a 125-kDa cytoplasmic protein tyrosine kinase that was named for its ability to localize to focal contacts(7, 8) . Published data obtained primarily using cultured fibroblasts have shown that engagement of integrins with ECM ligands or cross-linking of cell surface integrins with antibodies leads to a pronounced increase in the tyrosine phosphorylation of FAK (9, 10, 11, 12) and a concomitant increase in its intrinsic tyrosine kinase activity in vitro(13, 14) . The presence of tyrosine-phosphorylated proteins in focal contacts and the regulation of their tyrosine phosphorylation in response to integrin-mediated cell adhesion has led to the suggestion that FAK plays a central role in regulating focal contact assembly (10) .

Paxillin is a 68-kDa vinculin-binding protein that also colocalizes with FAK and integrins to focal contacts (15, 16) and is phosphorylated on tyrosine residues during integrin-mediated adhesion of fibroblasts to ECM substrates(10) . Paxillin has been identified as a target substrate for FAK phosphorylation in vitro(17, 18, 19) . On the basis of their colocalization to focal contacts and coordinate phosphorylation, it has been hypothesized that paxillin phosphorylation is closely coupled to FAK activation(10, 16, 19) . Recent evidence, however, suggests that the tyrosine phosphorylation of paxillin mediated by FAK may not be a critical determinant in paxillin localization to focal contacts(20) , suggesting that FAK phosphorylation of paxillin may serve an additional function possibly related to cell signaling(19, 20) .

The serine/threonine kinase, protein kinase C (PKC) is another regulatory enzyme that has been localized to focal contacts(21, 22) . Woods and Couchman (23) previously provided evidence in support of PKC involvement in the regulation of focal contact formation in fibroblasts. While it is well established that compounds that activate PKC such as phorbol 12-myristate 13-acetate (PMA) enhance cell adhesion and spreading on ECM substrates(24, 25, 26) , the identity of cytoskeletal proteins within focal contacts that serve as targets for PKC-mediated phosphorylation in response to integrin-dependent cell adhesion remain poorly defined. In the present study, we show that in M-CSF-treated macrophages, paxillin localizes to focal contacts in the absence of FAK expression and is predominantly serine-phosphorylated in response to integrin alpha(v)beta(5)-mediated adhesion to vitronectin. PMA stimulation of PKC activity was found to enhance paxillin phosphorylation, whereas selective inhibitors of PKC activity effectively block the phosphorylation of paxillin induced in response to vitronectin adhesion. These latter results indicate that serine phosphorylation of paxillin observed in response to vitronectin adhesion is thus PKC-dependent.


EXPERIMENTAL PROCEDURES

Monocyte Purification and Culture

Human peripheral blood cells were obtained by leukapheresis of normal volunteers at the Department of Transfusion Medicine at the National Institutes of Health. These cells were washed four times with 250 ml of Ca/Mg-free Hanks' balanced salt solution containing 2 mM EDTA to reduce platelet contamination, and then layered over a 20-ml Lymphoprep cushion (Nyegaard, Oslo) in 50-ml tubes (Falcon, Division of Becton Dickinson, Oxnard, CA). After density sedimentation at 400 times g for 20 min, the monocytes in the mononuclear cell layer were purified by counterflow centrifugal elutriation in a Beckman elutriation system as described previously (27) , except that phosphate-buffered saline (PBS) was used in the elutriation procedure. The method outlined above consistently yielded >94% pure monocytes as determined by flow cytometric, morphological, and cytochemical criteria as described(28) . Purified monocytes were resuspended in RPMI 1640 supplemented with 2 mM glutamine, 10 µg/ml gentamycin sulfate, and 10% (v/v) fetal bovine serum (heat inactivated). Cells were maintained in a nonadherent state in polystyrene Petri dishes (Nunc, Denmark) at 37 °C in 7.5% CO(2) and stimulated by human recombinant M-CSF (Genzyme, Cambridge MA) at 50 units/ml for 48 h. After 48 h in culture, these cells are referred to as M-CSF-treated macrophages.

Endotoxin Levels

Bacterial endotoxin is a potent regulator of leukocyte function(29) . To minimize its contamination, all monocyte purification and culturing was performed using sterile disposable plasticware, and only reagents of the highest quality were used. Fetal bovine serum (BioWhittaker, Walkersville, MD) was screened using the Limulus amoebocyte lysate assay and selected for low endotoxin content (0.5 enzyme units/ml) and the inability to support monocyte survival in the absence of exogenous stimuli; the M-CSF (purified recombinant cytokine expressed in yeast) was also shown to contain <0.03 unit/ml of endotoxin by this assay. RPMI 1640, PBS, Hanks' balanced salt solution, glutamine, and gentamycin sulfate (BioWhittaker) contained <0.005 endotoxin unit/ml as assayed by the manufacturer. Phosphate-free RPMI 1640 (Life Technologies, Inc./BRL, Gaithersburg, MD) contained <0.03 endotoxin unit/ml.

Fibroblast Cell Culture

Human foreskin fibroblasts were cultured in Dulbecco's modified Eagle's medium (Life Technologies, Inc./BRL) containing 2 mM glutamine, 50 µg/ml streptomycin, 50 units/ml penicillin, and 10% fetal bovine serum (HyClone, Logan, UT). The cells were isolated and kindly provided by Susan Yamada and were used at cell passages 4-8.

Antibodies

The monoclonal antibodies (mAbs) used were: LM142 (Chemicon International, Temecula, CA) directed against the alpha(v) subunit; SZ-21 (Immunotech, Westbrook, ME) which has specificity for the beta(3) subunit; B5-IVF2 (UBI, Lake Placid, NY) and P1F6 (Life Technologies, Inc./BRL) which recognize the beta(5) subunit and alpha(v)beta(5) complex, respectively. Monoclonal antibodies against paxillin and FAK were obtained from Transduction Laboratories (Lexington, KY), and antibody VII-F9B11 against human vinculin was a gift from Dr. Victor Koteliansky (CNRS-Institut Curie, Paris). Antibody 3G10 (Boehringer Mannheim) directed against the alpha-chain of the interleukin-2 receptor was used in immunoprecipitation studies as the isotype (IgG(1)) control. Polyclonal antiserum raised to c-src was obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).

Cell Lysate Preparation and Immunoprecipitation

Nonadherent/adherent macrophages or foreskin fibroblasts were washed twice with ice-cold PBS and solubilized in RIPA lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, and 2 mM EDTA) containing a variety of protease and phosphatase inhibitors (2 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 50 µg/ml soybean trypsin inhibitor, 20 mM iodoacetamide, 50 mM sodium fluoride, and 1 mM sodium orthovanadate) for 20 min on ice. The lysates were clarified by centrifugation at 20,000 times g for 15 min at 4 °C, and protein concentrations were determined using the bicinchoninic acid protein assay kit (Pierce). The lysates were adjusted to equal protein concentrations and volume and precleared overnight at 4 °C by incubating end-over-end with protein G-Sepharose beads (Pharmacia, Piscataway, NJ) and 30 µg of mouse IgG (Rockland, Gilbertsville, PA). The beads were sedimented by brief centrifugation, and immunoprecipitations were performed by incubating the precleared lysates with end-over-end mixing with the designated antibodies (4 µg/ml) together with protein G-Sepharose for 4 h at 4 °C. The beads were washed twice with ice-cold RIPA lysis buffer, then twice with the same buffer now containing 500 mM NaCl. The immunoprecipitated proteins were eluted by boiling in reducing SDS sample buffer (62 mM Tris-HCl, pH 6.8, 2.3% SDS, 10% glycerol, 5% beta-mercaptoethanol, and bromphenol blue) for 5 min.

Western Immunoblotting

Immunoprecipitates were resolved in 7.5% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose filters (Schleicher and Schuell) for 2 h at 250 mA. The filters were blocked with blocking buffer (5% BSA in TTBS; 150 mM NaCl, 50 mM Tris, 0.2% Tween 20, pH 7.4) for 3 h at room temperature and then incubated for 1 h with either the anti-paxillin or anti-FAK mAbs at 1 µg/ml in blocking buffer. After extensive washing at 37 °C with several changes of TTBS, the filters were incubated for 45 min with horseradish peroxidase-conjugated sheep anti-mouse IgG (Amersham) at a 1:3500 dilution in blocking buffer. After washing, immunoreactivity was detected by using the enhanced chemiluminescence (ECL) reaction (Amersham). To assess the tyrosine phosphorylation status of paxillin in response to vitronectin adhesion, blots were probed with horseradish peroxidase-conjugated PY-20 mAb (ICN) at a 1:7000 dilution. Filters were then stripped with 2% SDS, 100 mM beta-mercaptoethanol in 62.5 mM Tris-HCl, pH 6.8, for 30 min at 70 °C, and reprobed for paxillin as described above.

In Vivo Phosphorylation of Paxillin

In vivo phosphorylation studies were conducted as described(30) , with minor modifications. Nonadherent M-CSF-treated macrophages were harvested and endogenous phosphate levels depleted by washing twice with phosphate-free RPMI 1640, then resuspending the cells in phosphate-free RPMI 1640 containing 1 mg/ml bovine serum albumin (BSA) and incubating for 30 min at 37 °C. After phosphate starvation, the cells were biosynthetically labeled by incubating in phosphate-free RPMI 1640 containing 1 mg/ml BSA and 150 µCi/ml [P]orthophosphate (9000 Ci/mmol; DuPont NEN) for 90 min at 37 °C. Macrophages were then stimulated under the various conditions as described while in the continuous presence of [P]orthophosphate. Paxillin phosphorylation was assessed by immunoprecipitation followed by SDS-PAGE and autoradiography. The protein kinase C inhibitors GF109203X (Boehringer Mannheim) and chelerythrine chloride (LC Laboratories, Woburn, MA), when used, were added to the cells during the final 60 min incubation with [P]orthophosphate prior to stimulation, and were maintained in the culture medium throughout. Stock solutions of GF109203X (5 mM), chelerythrine chloride (10 mM), and the protein kinase C activator PMA (5 mg/ml) were dissolved in dimethyl sulfoxide. PMA was obtained from Sigma. Phosphoamino acid analysis was performed essentially as described by Siegel(30) . Autoradiographs were scanned using a laser densitometer (Personal Densitometer SI, Molecular Dynamics, Sunnyvale, CA) and the results expressed as arbitrary units normalized against background.

Attachment to Vitronectin

Vitronectin was purified from human serum according to the method of Yatohgo et al.(31) , and its purity was determined by SDS-PAGE and Coomassie Blue staining. For immunofluorescence localization studies, sterile glass coverslips (18 mm) were placed into 12-well plates (Nunc) and coated at 4 °C overnight with human vitronectin (50 µg/ml in 0.5 ml of PBS). Cultured macrophages were harvested, washed twice with RPMI 1640, and resuspended in RPMI 1640 containing 1 mM CaCl(2) and BSA at 1 mg/ml; cells (10^5 per well) were allowed to adhere for 60 min at 37 °C, and nonadherent cells were removed by gentle washing. For phosphorylation studies, polystyrene Petri dishes (100 times 15 mm; Nunc) were coated overnight at 4 °C with vitronectin (50 µg/ml in 4 ml of PBS).

Indirect Immunofluorescence

Macrophages were allowed to attach and spread on uncoated or vitronectin-coated coverslips and stained by indirect immunofluorescence as described(28) .

Adhesion Assays

Cell adhesion assays were performed as described previously with modifications(32) . In brief, sterile tissue culture grade 96-well cluster plates (Costar, Cambridge, MA) were coated with 100 µl/well of vitronectin (0.1-100 µg/ml in PBS) at 4 °C overnight, and then blocked with alpha-casein (1.5 mg/ml in PBS) for 1 h at 37 °C immediately before use. Macrophages were harvested, washed twice with RPMI 1640, and resuspended to 2.5 times 10^6 cells/ml in RPMI 1640 containing 1 mM CaCl(2) and 1 mg/ml BSA. A 100-µl volume of the cell suspension was added to each well and the plates were incubated for 30 min at 37 °C. After the attachment period, nonadherent cells were poured off and residual cells stained with 0.25% (w/v) Rose Bengal dye (Sigma) in PBS for 10 min at room temperature. The wells were then washed twice with PBS and the remaining dye was released by incubating with 100 µl/well 50% ethanol in PBS. Released dye was quantified as absorbance at 560 nm using a microplate reader (Titertek Multiskan, Flow Laboratories, McLean, VA). To assay inhibition of attachment, cells were pretreated with various dilutions of either mAbs P1F6 or LM142 in the form of unpurified ascites for 30 min on ice prior to assay. Results are expressed as the mean ± S.E. of triplicate determinations.

Flow Cytometric Analysis

Macrophages, 5 times 10^5 in PBS, were held on ice for 45 min in the presence of a 1:10 dilution of non-immune goat serum (ICN) to block nonspecific binding sites. Cells were washed once in FACS wash (5% fetal bovine serum, 0.2% sodium azide in PBS) and incubated with the primary mAbs (5 µg/ml) for 60 min on ice. Cells were subsequently washed twice with FACS wash and treated with the secondary antibody (1:100 dilution of fluorescein-conjugated goat F(ab`)(2) anti-mouse IgG) for 30 min on ice. After washing twice with FACS wash, the cells were resuspended in 0.5 ml of FACS fix (2% glucose, 1% formaldehyde, 0.02% sodium azide in PBS) and analyzed for fluorescence using a flow cytometer (FACScan, Becton Dickinson, San Jose, CA). Background staining was assessed by omitting the primary antibody.


RESULTS

M-CSF-treated Macrophages Express alpha(v) Only in Association with beta(5)

We reported previously that the colony-stimulating factor M-CSF was able to induce the expression of the alpha(v)beta(5) integrin receptor on the surface of cultured human macrophages(28) . To confirm and extend these observations, flow cytometric analyses were performed on M-CSF-treated macrophages using mAbs directed against the beta(5) subunit and alpha(v)beta(5) complex that were not available at the time of our earlier study. Fig. 1demonstrates that the fluorescence intensity of cell surface staining for both the beta(5) subunit and the alpha(v)beta(5) complex were equivalent to the levels observed for the alpha(v) subunit. In contrast, the anti-beta(3) mAb exhibited levels of immunostaining no greater to that of control cells where the primary antibody had been omitted. Our previous study indicated that M-CSF-treated macrophages fail to express the integrin alpha(v)beta(1) as was shown by preclearing beta(5) from a lysate of surface radioiodinated cells and demonstrating that after sequential clearance there was no residual alpha(v)(28) . Taken together, these data indicate that M-CSF-treated macrophages express alpha(v) only in association with the beta(5) subunit.


Figure 1: Flow cytometric analysis of surface alpha integrin expression. M-CSF-treated macrophages were stained with mAb LM142 to the alpha(v) subunit (alpha(v)), mAb SZ-21 to the beta(3) subunit (beta(3)), mAb B5-IVF2 to the beta(5) subunit (beta(5)), or mAb P1F6 to the alpha(v)beta(5) complex (alpha(v)beta(5)) (solid peaks). Cells were then treated with fluorescein-conjugated goat F(ab`)(2) anti-mouse IgG, washed, and analyzed by flow cytometry. Control cells (open peaks) were stained with the secondary antibody alone. Results are depicted as histograms with fluorescence intensity on the abscissa and cell number on the ordinate.



Integrin alpha(v)beta(5) Mediates the Adhesion of M-CSF-treated Macrophages to Vitronectin

Fig. 2A shows that M-CSF-treated macrophages adhere to vitronectin in a dose-dependent manner, with half-maximal adhesion achieved at a coating concentration of 1 µg/ml and reaching a plateau at approximately 10 µg/ml. To investigate whether alpha(v)beta(5) was the integrin responsible for mediating the adhesion of M-CSF-treated macrophages to vitronectin, cell adhesion assays were performed in the presence of specific anti-integrin monoclonal antibodies. As shown in Fig. 2B, mAb P1F6 directed against a functional epitope on integrin alpha(v)beta(5) substantially inhibited the adhesion of M-CSF-treated macrophages to vitronectin in a dose-dependent manner. In contrast, the non-inhibitory anti-alpha(v) mAb LM142 which served both as an IgG isotype and ascites control, failed even at the highest concentration to influence the adhesion of M-CSF-treated macrophages to vitronectin. These data demonstrate that the adhesion of M-CSF-treated macrophages to vitronectin is mediated by the integrin alpha(v)beta(5).


Figure 2: Inhibition of macrophage adhesion to vitronectin. A, M-CSF-treated macrophages were allowed to attach and spread on wells coated with vitronectin (0-100 µg/ml) for 30 min at 37 °C. Nonadherent cells were removed by gentle washing, and cell adhesion was quantitated as described under ``Experimental Procedures.'' The data represent the mean ± S.E. of triplicate determinations. B, M-CSF-treated macrophages were pretreated with various dilutions of either mAb P1F6 (anti-alpha(v)beta(5)) or mAb LM142 (control) for 30 min on ice, then added to wells coated with 1 µg/ml vitronectin and allowed to attach and spread for 30 min at 37 °C. Cell adhesion was quantitated as described under ``Experimental Procedures.'' Results are shown as percent of maximum adhesion, as defined by cell binding to wells in the absence of antibodies. Data are expressed as mean ± S.E. of triplicate determinations.



Integrin alpha(v)beta(5) and Paxillin Localize to Focal Contacts on Vitronectin

Evidence for the functional involvement of integrins in cell spreading on a particular substrate can be obtained directly by examining the distribution of the receptors involved. This was accomplished by permitting M-CSF-treated macrophages to adhere to vitronectin for 60 min and examining these cells for the distribution of the beta(5) subunit by indirect immunofluorescence analysis. As shown in Fig. 3B, beta(5) staining in permeabilized cells was localized to streaks, both peripheral and under the cell body. In these cells, the streaks could be identified as focal contacts by both vinculin (Fig. 3C) and talin staining (data not shown). Staining with anti-paxillin mAb also revealed the localization of paxillin to focal contacts in cells adherent to vitronectin (Fig. 3D).


Figure 3: Localization of integrin beta(5), paxillin, and vinculin distribution by indirect immunofluorescence. M-CSF-treated macrophages were allowed to attach and spread on vitronectin-coated coverslips under serum-free conditions for 60 min. Cells were fixed, permeabilized, and stained with: A, secondary fluorescein-conjugated antibody alone; B, mAb B5-IVF2 to the beta(5) subunit; C, mAb VII-F9B11 to vinculin; D, mAb to paxillin. Focal contacts are highlighted by arrowheads. Bar = 5 µm.



Localization of Paxillin to Focal Contacts Is Independent of FAK Expression

FAK is a 125-kDa cytoplasmic protein tyrosine kinase thought to play a central role in orchestrating focal contact formation in response to integrin-mediated cell adhesion to the extracellular matrix(8) . In particular, it has been suggested that the localization of paxillin to focal contacts and its phosphorylation on tyrosine are closely coupled to FAK activation(10) . A recent report found that human monocytes freshly isolated from peripheral blood fail to express FAK(33) . Based on these observations, we examined whether M-CSF, in addition to its ability to regulate alpha(v)beta(5) expression, could also regulate the expression of FAK in cultured human macrophages, thereby facilitating the localization of paxillin to focal contacts in response to alpha(v)beta(5)-mediated adhesion to vitronectin. Immunoprecipitation and Western blot analysis revealed that while M-CSF-treated macrophages express abundant paxillin, these cells do not express FAK (Fig. 4). As a positive control, FAK could be readily detected in whole cell lysates obtained from human foreskin fibroblasts (Fig. 4). Indirect immunofluorescence localization studies using mAbs and a polyclonal antiserum raised against FAK have also confirmed the absence of FAK in M-CSF-treated macrophages adherent to vitronectin (data not shown). We therefore conclude that the localization of paxillin to focal contacts in M-CSF-treated macrophages adherent to vitronectin occurs independent of FAK expression.


Figure 4: Analysis of FAK protein expression. Left, total cell lysates (1 mg) from human foreskin fibroblasts (lanes 1 and 2) or M-CSF-treated macrophages (lanes 3 and 4) were immunoprecipitated with either an isotype control mAb (lanes 1 and 3) or an anti-FAK mAb (lanes 2 and 4). The precipitated immunocomplexes were analyzed for FAK expression by Western immunoblotting. Right, as a control, total cell lysates (1 mg) from M-CSF-treated macrophages were immunoprecipitated with either an isotype control mAb (lane 5) or an anti-paxillin mAb (lane 6). The precipitated immunocomplexes were analyzed for paxillin expression by Western immunoblotting.



Paxillin Is Predominantly Serine-phosphorylated in Response to Vitronectin Adhesion

In light of the observation that M-CSF-treated macrophages fail to express FAK, experiments were undertaken to determine whether or not paxillin could be tyrosine-phosphorylated in response to vitronectin adhesion. Total cell lysates from M-CSF-treated macrophages that were maintained either in a nonadherent state or allowed to attach and spread on uncoated or vitronectin-coated dishes for 60 min, were immunoprecipitated with a monoclonal anti-paxillin antibody and analyzed by Western immunoblotting using an anti-phosphotyrosine monoclonal antibody. As shown in Fig. 5D, paxillin was specifically tyrosine-phosphorylated, albeit at very low levels, in response to vitronectin adhesion. In contrast, tyrosine phosphorylation of paxillin was not observed in nonadherent cells or in cells adherent to plastic. Interestingly, reprobing the blots to confirm equal protein loading revealed the presence of a slower migrating form of paxillin immunoprecipitated from macrophages adherent to vitronectin (Fig. 5D). Indirect immunofluorescence analysis reveals a close association between paxillin localization to focal contacts (Fig. 5B) and the tyrosine phosphorylation and mobility shift of paxillin observed in M-CSF-treated macrophages upon adhesion to vitronectin (Fig. 5D). In contrast, paxillin remains diffusely distributed in cells that attach and spread on uncoated coverslips over the same time period (Fig. 5A).


Figure 5: Analysis of paxillin tyrosine phosphorylation. M-CSF-treated macrophages were allowed to attach and spread on uncoated (A and C) or vitronectin-coated (B) coverslips in serum-free conditions for 60 min. Cells were fixed, permeabilized and stained with: A and B, mAb to paxillin; or C, secondary fluorescein-conjugated antibody alone. Bar = 10 µm. D, M-CSF-treated macrophages were harvested and maintained in a nonadherent state for 60 min (lane 1), or allowed to attach and spread on either uncoated (lane 2) or vitronectin-coated (lane 3) Petri dishes for 60 min. Cells were solubilized in RIPA lysis buffer, and paxillin was immunoprecipitated from equal concentrations and volumes of cell lysate. The precipitated immunocomplexes were separated by SDS-PAGE and probed by Western immunoblotting with the anti-phosphotyrosine mAb PY-20 (anti-PY). The filter was then stripped and reprobed with the anti-paxillin mAb (anti-paxillin). Note that in lane 3, staining for paxillin reveals substantial broadening of the band by more slowly migrating material. It should also be noted that the exposure time of the anti-PY blot to autoradiographic film was 10 min, whereas the anti-paxillin blot was exposed for 10 s.



Zachary et al. (34) reported a similar mobility shift of paxillin in Swiss 3T3 fibroblasts stimulated with bombesin. These authors noted that even though paxillin was strongly tyrosine-phosphorylated in response to bombesin stimulation, inhibition of the PKC pathway either by down-regulation of PKC or treatment with the selective PKC inhibitor GF109203X blocked this characteristic mobility shift of paxillin without influencing the levels of tyrosine phosphorylation, thus suggesting the potential involvement of serine/threonine phosphorylation. Based on these observations, we examined directly whether paxillin could be phosphorylated on serine/threonine residues in response to alpha(v)beta(5)-mediated adhesion to vitronectin. Fig. 6A shows that in M-CSF-treated macrophages labeled with [P]orthophosphate, paxillin was heavily phosphorylated in response to vitronectin adhesion. This phosphorylation appeared to be a specific integrin-mediated response, because very little [P]orthophosphate was incorporated into paxillin that was immunoprecipitated from cells either maintained in a nonadherent state or allowed to attach and spread on plastic over the same period of time (Fig. 6A). Two-dimensional phosphoamino acid analysis revealed that 99% of the [P]orthophosphate incorporated into paxillin upon adhesion to vitronectin was on serine residue(s) (Fig. 6B). In contrast, phosphorylation on tyrosine residue(s) accounted for only 1% of the total paxillin phosphorylation, a figure that is consistent with the low levels of paxillin tyrosine phosphorylation observed by Western immunoblotting (Fig. 5D). Phosphorylation on threonine residue(s) was not detected by phosphoamino acid analysis under the conditions described (Fig. 6B). These data provide the first evidence for serine phosphorylation of paxillin in response to integrin-mediated adhesion to vitronectin.


Figure 6: Analysis of total paxillin phosphorylation. A, M-CSF-treated macrophages were labeled with [P]orthophosphate as described under ``Experimental Procedures,'' then maintained either in a nonadherent state for 60 min (lane 1), or allowed to attach and spread on uncoated (lane 2) or vitronectin-coated (lane 3) Petri dishes for 60 min. Cells were solubilized in RIPA lysis buffer, and equal concentrations and volumes of cell lysates were immunoprecipitated using an anti-paxillin mAb. The precipitated immunocomplexes were visualized following SDS-PAGE and autoradiography. B, the phosphorylated band corresponding to paxillin was excised and subjected to two-dimensional phosphoamino acid analysis as described under ``Experimental Procedures.'' PT (phosphothreonine), PY (phosphotyrosine), and PS (phosphoserine) indicate the relative migration of the phosphoamino acid standards. The smear running below and to the left of the PY area represents phosphopeptides generated by incomplete acid hydrolysis.



PMA Activation of PKC Enhances the Phosphorylation of Paxillin

Cloning and sequence analysis has revealed that paxillin contains six potential consensus target phosphorylation sites for PKC (18, 35) . To determine whether direct activation of PKC could enhance paxillin phosphorylation, M-CSF-treated macrophages were labeled with [P]orthophosphate and allowed to attach and spread on vitronectin-coated dishes for 60 min in the absence or presence of the PKC activator PMA. As shown in Fig. 7A, PMA stimulation of M-CSF-treated macrophages on vitronectin resulted in a 2.5-fold increase in paxillin phosphorylation as compared to the levels observed in the absence of PMA stimulation. This enhanced phosphorylation mediated by PMA stimulation was also accompanied by a shift in the relative mobility of paxillin (Fig. 7A). Turner et al. (36) recently demonstrated an increase in paxillin tyrosine phosphorylation following stimulation of rat aortic smooth muscle cells with PMA. Anti-phosphotyrosine Western blotting of paxillin immunoprecipitates prepared from lysates obtained from macrophages treated under parallel conditions to those described in Fig. 7A revealed no increase in the level of paxillin tyrosine phosphorylation upon PMA treatment (data not shown), suggesting the increase in phosphorylation mediated by PMA was likely to be on serine/threonine residue(s). Next, we examined the effect of PMA stimulation on the kinetics of paxillin phosphorylation in cells on vitronectin. As shown in Fig. 7B, adhesion of M-CSF-treated macrophages to vitronectin in the absence of PMA stimulation resulted in a time-dependent increase in paxillin phosphorylation, that was first evident within 15 min following cell attachment and began to plateau by 60 min. Stimulation with PMA clearly enhanced the rate and magnitude of paxillin phosphorylation over the same time period (Fig. 7B). The levels of paxillin phosphorylation observed in Fig. 7B closely parallel the time course of adhesion and spreading of M-CSF-treated macrophages to vitronectin under the same conditions (data not shown). PMA stimulation was also found to enhance the recruitment of both integrin alpha(v)beta(5) and paxillin to focal contacts. The effect of PMA stimulation on paxillin localization to focal contacts is illustrated in Fig. 8. Indirect immunofluorescence analysis indicates that cells spreading on vitronectin over a 60-min period in the presence of PMA have a greater number of focal contacts containing paxillin as compared to cells that attach and spread on vitronectin in the absence of PMA treatment (Fig. 8).


Figure 7: Effect of PMA on paxillin phosphorylation. A, M-CSF-treated macrophages were labeled with [P]orthophosphate as described under ``Experimental Procedures.'' Cells were subsequently maintained either in a nonadherent state for 60 min (lane 1), or allowed to attach and spread on vitronectin-coated dishes for 60 min in the absence (lane 2) or presence of 5 ng/ml PMA (lane 3). To assess paxillin phosphorylation, cells were solubilized in RIPA lysis buffer and equal concentrations and volumes of cell lysates were immunoprecipitated using an anti-paxillin mAb. The precipitated immunocomplexes were visualized following SDS-PAGE and autoradiography. B, M-CSF-treated macrophages were labeled with [P]orthophosphate as described under ``Experimental Procedures.'' Cells were then allowed to attach and spread on vitronectin-coated dishes for time points up to and including 60 min in the presence or absence of 5 ng/ml PMA. Paxillin phosphorylation was assessed as described above in A. Autoradiographs were scanned by laser densitometry and results expressed as arbitrary units normalized against background.




Figure 8: Effects of PMA and chelerythrine chloride on paxillin localization to focal contacts. M-CSF-treated macrophages were allowed to attach and spread on vitronectin-coated coverslips under serum-free conditions for 60 min in the absence (A) or presence (B) of 5 ng/ml PMA. Cells were fixed, permeabilized, and stained with mAb to paxillin. Focal contacts are highlighted by arrowheads. In panel C, cells were pretreated with 1 µM chelerythrine chloride for 60 min prior to attachment and spreading on vitronectin for an additional 60 min in the absence of PMA. Cells were then fixed, permeabilized, and stained with mAb to paxillin. Cells pretreated with GF109203X revealed a staining pattern that was virtually identical to that seen in panel C for chelerythrine chloride. Bar = 10 µm.



Inhibition of PKC Activity Blocks alpha(v)beta(5)-mediated Serine Phosphorylation of Paxillin

To further examine the involvement of PKC in mediating serine phosphorylation of paxillin in response to vitronectin adhesion, we employed two potent inhibitors of PKC activity, the bisindolylmaleimide GF109203X and chelerythrine chloride. Both compounds have been reported to be highly selective for PKC, with GF109203X able to compete for ATP binding(37) , while chelerythrine chloride inhibits the catalytic domain of PKC(38) . Fig. 9shows that pretreatment of [P]orthophosphate labeled M-CSF-treated macrophages with either GF109203X (10 µM) or chelerythrine chloride (1 µM) effectively inhibited the serine phosphorylation of paxillin induced in response to vitronectin adhesion. The effect of the inhibitors appeared to be specific, as neither GF109203X nor chelerythrine chloride were able to influence the adhesion-dependent phosphorylation of Src (Fig. 9). It is also of interest to note that pretreatment of human macrophages with either GF109203X or chelerythrine chloride was also found to substantially inhibit the low levels of paxillin tyrosine phosphorylation induced in response to vitronectin adhesion. Densitometric analysis of anti-phosphotyrosine Western blots revealed the extent of inhibition to be greater than 95% for both GF109203X and chelerythrine chloride. These data demonstrate that alpha(v)beta(5)-mediated phosphorylation of paxillin is PKC-dependent. Indirect immunofluorescence analysis also revealed that treatment with either GF109203X or chelerythrine chloride at concentrations shown to inhibit the phosphorylation of paxillin also inhibited the formation of focal contacts as assessed by the absence of integrin beta(5), paxillin, and vinculin staining in organized structures resembling focal contacts. Fig. 8C demonstrates the inhibitory effect chelerythrine chloride pretreatment has on paxillin localization to focal contacts.


Figure 9: Effect of PKC inhibitors GF109203X and chelerythrine chloride on paxillin phosphorylation. M-CSF-treated macrophages were labeled with [P]orthophosphate and pretreated with either dimethyl sulfoxide (vehicle control) (lanes 1, 2, and 4), 10 µM GF109203X (lane 3), or 1 µM chelerythrine chloride (lane 5) for 60 min as described under ``Experimental Procedures.'' Cells were then maintained either in a nonadherent state for 60 min (lane 1), or allowed to attach and spread on vitronectin-coated Petri dishes for 60 min (lanes 2-5). To assess the phosphorylation status of both paxillin and Src, cells were solubilized in RIPA lysis buffer and equal concentrations and volumes of cell lysates immunoprecipitated using either an anti-paxillin mAb (paxillin) or a polyclonal antisera raised against c-src (src). The precipitated immunocomplexes were visualized by autoradiography after SDS-PAGE.




DISCUSSION

We previously reported that the colony-stimulating factor M-CSF is able to induce expression of the alpha(v)beta(5) integrin receptor on the surface of cultured human macrophages(28) . Moreover, we found that in M-CSF-treated macrophages adherent to vitronectin, alpha(v) staining was localized to focal contacts. However, the identity of the beta subunit associating with alpha(v) in focal contacts could not be demonstrated definitively(28) . Here, we confirm by using mAbs to the beta(5) subunit and alpha(v)beta(5) complex that M-CSF-treated macrophages express alpha(v) only in association with beta(5), and extend these observations to demonstrate that these cells adhere to vitronectin in an alpha(v)beta(5)-dependent manner. Indirect immunofluorescence analysis establishes definitively the localization of alpha(v)beta(5) to focal contacts, suggesting the surface expression of alpha(v)beta(5) on cultured human macrophages is a determining factor in their morphology on vitronectin.

We find that like the integrin alpha(v)beta(5), paxillin, a vinculin-binding protein (15, 16) also localizes to focal contacts in M-CSF-treated macrophages adherent to vitronectin. FAK is thought to play a central role in the organization of the cytoskeleton as cells adhere to the ECM. In particular, it has been suggested that the localization of paxillin to focal contacts and its phosphorylation on tyrosine are tightly coupled to FAK activation(10) . We demonstrate here by immunoprecipitation and Western blot analysis, together with indirect immunofluorescence studies, that M-CSF-treated macrophages do not express FAK. These observations are consistent with previous reports in mouse bone marrow-derived macrophages(39) , and in human peripheral blood monocytes (33) that demonstrate the absence of FAK expression at both the RNA and protein levels, respectively. Our findings and particularly those described by Juliano's group (33) are somewhat at variance with the observations recently reported by Kharbanda et al.(40) . These authors reported the presence of FAK protein in human monocytes freshly isolated from peripheral blood. The reason for this discrepancy is not known; one distinct possibility, however, is that FAK observed in these cells is not of monocyte origin, but is rather derived from contaminating platelet microparticles that are rich in FAK and are known to bind to the surface of activated monocytes as a direct result of monocyte purification by adhesion to plastic(41) , the same method used by Kharbanda et al.(40) . It is well established that monocyte purification by counterflow centrifugal elutriation does not result in the activation of these cells as assessed by the absence of interleukin-2 receptor expression, a sensitive marker of monocyte activation(42) . The monocytes prepared in this laboratory and that of Juliano's (33) were isolated by counterflow centrifugal elutriation, so it is therefore not surprising that both studies reach the same conclusion that monocytes/macrophages do not express FAK.

This study provides direct evidence for integrin-dependent localization of paxillin to focal contacts in the absence of FAK, and is consistent with a recent report demonstrating focal contact formation in cells derived from FAK-deficient mice(43) . Our observations expand the implications of recent findings that the process of tyrosine phosphorylation of paxillin by FAK is not a critical determinant in the localization of paxillin to focal contacts (20) , and that paxillin can undergo tyrosine phosphorylation in the absence of FAK(43) . Although the underlying molecular mechanism responsible for mediating paxillin localization to focal contacts is currently open to speculation, Schaller et al.(44) recently established that paxillin is able to bind specifically to synthetic peptides that mimic integrin beta subunit cytoplasmic domains. Whether paxillin binding is a direct or indirect interaction is presently unresolved, although it is apparent from these studies that the interaction occurs independent of FAK(44) . Our own observations, coupled with those of other laboratories raise the distinct possibility that upon adhesion of M-CSF-treated macrophages to vitronectin, the localization of paxillin to focal contacts may occur via interaction with the integrin beta(5) subunit cytoplasmic domain.

One of the major observations communicated in this report is the demonstration by phosphoamino acid analysis that paxillin is 99% phosphorylated on serine residue(s) in response to alpha(v)beta(5)-mediated adhesion to vitronectin. While much attention in the literature has focused on the phosphorylation of paxillin on tyrosine residues, serine phosphorylation of paxillin in response to integrin-mediated cell adhesion to the ECM was previously overlooked, despite the knowledge that paxillin contains multiple consensus target sites for a number of serine/threonine kinases, including PKC(18) , cAMP-dependent protein kinase, casein kinase II, p34, and S6 kinase. Our observations indicate that in M-CSF-treated macrophages adherent to vitronectin, the serine phosphorylation of paxillin is mediated via a PKC-dependent mechanism. We provide evidence to show that direct stimulation of PKC activity with the phorbol ester PMA enhances paxillin phosphorylation, whereas two selective inhibitors of PKC, GF109203X and chelerythrine chloride, specifically and effectively block the phosphorylation of paxillin induced in response to vitronectin adhesion. Whether the phosphorylation of paxillin on serine is directly mediated by PKC, or alternatively, whether PKC acts indirectly to modulate the activity of other serine/threonine kinase(s) that phosphorylate paxillin is yet to be determined. Inhibition of paxillin serine phosphorylation was found to correlate with inhibition of focal contact formation in M-CSF-treated macrophages adherent to vitronectin. PKC-mediated phosphorylation changes may be an important mechanism in the assembly of focal contacts(23) . The localization of PKC to focal contacts (21, 22) supports this potential role of PKC and therefore serine/threonine phosphorylation in focal contact assembly and cell spreading.

In addition to serine phosphorylation, we also demonstrate the phosphorylation of paxillin on tyrosine residue(s), albeit at very low levels, in response to alpha(v)beta(5)-mediated adhesion of macrophages to vitronectin. In the absence of FAK expression, these data suggest that paxillin serves as a substrate for a protein-tyrosine kinase other than FAK. One obvious candidate to fulfill this role is the cytoplasmic protein-tyrosine kinase pp60, which was recently shown to phosphorylate paxillin on tyrosine in vitro at sites that become phosphorylated in vivo(19) . Our own observations demonstrate concomitant phosphorylation of both Src and paxillin in response to integrin-mediated adhesion of M-CSF-treated macrophages to vitronectin, suggesting that paxillin tyrosine phosphorylation is coupled to Src kinase activity. The precise role of integrin-mediated tyrosine phosphorylation of paxillin remains unknown. Recent evidence indicates that tyrosine phosphorylation of paxillin is not essential for the localization of paxillin to focal contacts(20) . Phosphorylation of paxillin on tyrosine residues, however, has been reported to create binding sites for the SH2 domains of the protein-tyrosine kinases Csk (45) and Src(46) , as well as the oncoprotein Crk(19, 47) , suggesting paxillin may serve a role in signal transduction as an adaptor protein to facilitate the recruitment of signaling molecules to focal contact sites(8) .

Our findings that paxillin localizes to focal contacts in the absence of FAK expression and is predominantly phosphorylated on serine residue(s) in response to vitronectin adhesion are intriguing, particularly in light of the recent report that tyrosine phosphorylation of paxillin is not essential for its recruitment to focal contacts(20) . Whether serine phosphorylation of paxillin alone is the critical determinant in its localization to focal contacts remains to be determined, but the 99:1 predominance of serine to tyrosine phosphorylation suggests a significant functional role for this major extracellular substrate-dependent modification.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Laboratory of Developmental Biology, National Institute of Dental Research, Bldg. 30, Rm. 404, 30 Convent Dr. MSC 4370, Bethesda, MD 20892-4370. Tel.: 301-402-1558; Fax: 301-402-0897; mnichilo{at}yoda.nidr.nih.gov.

(^1)
The abbreviations used are: ECM, extracellular matrix; M-CSF, macrophage colony-stimulating factor; mAb, monoclonal antibody; PAGE, polyacrylamide gel electrophoresis; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PY, phosphotyrosine; FAK, focal adhesion kinase; PBS, phosphate-buffered saline; BSA, bovine serum albumin.


ACKNOWLEDGEMENTS

We extend many thanks to Dr. Susan Leitman and the staff of the Department of Transfusion Medicine at the National Institutes of Health for their excellent preparation of leukapheresis packs. We also thank Dr. Larry M. Wahl, Laboratory of Immunology, NIDR at NIH, for use of the elutriation system and for his valuable advice on monocyte preparation.


REFERENCES

  1. Damsky, C. H., and Werb, Z. (1992) Curr. Opin. Cell Biol. 4, 772-781 [Medline] [Order article via Infotrieve]
  2. Hynes, R. O. (1992) Cell 69, 11-25 [Medline] [Order article via Infotrieve]
  3. Juliano, R. L., and Haskill, S. (1993) J. Cell Biol. 120, 577-585 [Medline] [Order article via Infotrieve]
  4. Yamada, K. M., and Miyamoto, S. (1995) Curr. Opin. Cell Biol. 7, 681-689 [CrossRef][Medline] [Order article via Infotrieve]
  5. Schwartz, M. A., Schaller, M. D., and Ginsberg, M. H. (1995) Annu. Rev. Cell Dev. Biol. 11, 549-599 [CrossRef][Medline] [Order article via Infotrieve]
  6. Turner, C. E., and Burridge, K. (1991) Curr. Opin. Cell Biol. 3, 849-853 [Medline] [Order article via Infotrieve]
  7. Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196 [Abstract]
  8. Schaller, M. D., and Parsons, J. T. (1994) Curr. Opin. Cell Biol. 6, 705-710 [Medline] [Order article via Infotrieve]
  9. Guan, J.-L., Trevithick, J. E., and Hynes, R. O. (1991) Cell Regul. 2, 951-964 [Medline] [Order article via Infotrieve]
  10. Burridge, K., Turner, C. E., and Romer, L. H. (1992) J. Cell Biol. 119, 893-903 [Abstract]
  11. Hanks, S. K., Calalb, M. B., Harper, M. C., and Patel, S. K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8487-8491 [Abstract]
  12. Kornberg, L. J., Earp, H. S., Turner, C. E., Prockop, C., and Juliano, R. L. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8392-8396 [Abstract]
  13. Lipfert, L., Haimovich, B., Schaller, M. D., Cobb, B. S., Parsons, J. T., and Brugge, J. S. (1992) J. Cell Biol. 119, 905-912 [Abstract]
  14. Guan, J.-L., and Shalloway, D. (1992) Nature 358, 690-692 [CrossRef][Medline] [Order article via Infotrieve]
  15. Turner, C. E., Glenney, J. R., Jr., and Burridge, K. (1990) J. Cell Biol. 111, 1059-1068 [Abstract]
  16. Turner, C. E. (1994) BioEssays 16, 47-52 [Medline] [Order article via Infotrieve]
  17. Turner, C. E., Schaller, M. D., and Parsons, J. T. (1993) J. Cell Sci. 105, 637-645 [Abstract/Free Full Text]
  18. Turner, C. E., and Miller, J. T. (1994) J. Cell Sci. 107, 1583-1591 [Abstract/Free Full Text]
  19. Schaller, M. D., and Parsons, J. T. (1995) Mol. Cell. Biol. 15, 2635-2645 [Abstract]
  20. Bellis, S. L., Miller, J. T., and Turner, C. E. (1995) J. Biol. Chem. 270, 17437-17441 [Abstract/Free Full Text]
  21. Jaken, S., Leach, K., and Klauck, T. (1989) J. Cell Biol. 109, 697-704 [Abstract]
  22. Barry, S. T., and Critchley, D. R. (1994) J. Cell Sci. 107, 2033-2045 [Abstract/Free Full Text]
  23. Woods, A., and Couchman, J. R. (1992) J. Cell Sci. 101, 277-290 [Abstract]
  24. Mercurio, A. M., and Shaw, L, M. (1988) J. Cell Biol. 107, 1873-1880 [Abstract]
  25. Danilov, Y. N., and Juliano, R. L. (1989) J. Cell Biol. 108, 1925-1933 [Abstract]
  26. Vuori, K., and Ruoslahti, E. (1993) J. Biol. Chem. 268, 21459-21462 [Abstract/Free Full Text]
  27. Wahl, L. M., and Smith, P. (1991) in Current Protocols in Immunology (Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W., eds) pp. 7.6.1-7.6.6, John Wiley & Sons, Inc., New York
  28. De Nichilo, M. O., and Burns, G. F. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2517-2521 [Abstract]
  29. Thorens, B., Mermod, J., and Vassalli, P. (1987) Cell 48, 671-679 [Medline] [Order article via Infotrieve]
  30. Siegel, J. N. (1991) in Current Protocols in Immunology (Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W., eds) pp. 11.2.1-11.2.7, John Wiley & Sons, Inc., New York
  31. Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M. (1988) Cell Struct. Funct. 13, 281-292 [Medline] [Order article via Infotrieve]
  32. Burns, G. F., Lucas, C. M., Krissansen, G. W., Werkmeister, J. A., Scanlon, D. B, Simpson, R. J., and Vadas, M. A. (1988) J. Cell Biol. 107, 1125-1230
  33. Lin, T. H., Yurochko, A., Kornberg, L., Morris, J., Walker, J. J., Haskill, S., and Juliano, R. L. (1994) J. Cell Biol. 126, 1585-1593 [Abstract]
  34. Zachary, I., Sinnett-Smith, J., Turner, C. E., and Rozengurt, E. (1993) J. Biol. Chem. 268, 22060-22065 [Abstract/Free Full Text]
  35. Salgia, R., Li, J. L., Lo, S. H., Brunkhorst, B., Kansas, G. S., Sobhany, E. S., Sun, Y., Pisick, E., Hallek, M., Ernst, T., Tantravahi, R., Chen, L. B., and Griffin, J. D. (1994) J. Biol. Chem. 270, 5039-5047 [Abstract/Free Full Text]
  36. Turner, C. E., Pietras, K. M., Taylor, D. S., and Molloy, C. J. (1995) J. Cell Sci. 108, 333-342 [Abstract/Free Full Text]
  37. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., Duhamel, L., Charon, D., and Kirilovsky, J. (1991) J. Biol. Chem. 266, 15771-15781 [Abstract/Free Full Text]
  38. Herbert, J. M., Augereau, J. M., Gleye, J., and Maffrand, J. P. (1990) Biochem. Biophys. Res. Commun. 17, 993-999
  39. Choi, K., Kennedy, M., and Keller, G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5747-5751 [Abstract]
  40. Kharbanda, S., Saleem, A., Yuan, Z., Emoto, Y., Prasad, E. V. S., and Kufe, D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6132-6136 [Abstract/Free Full Text]
  41. Krissansen, G. W., Lucas, C. M., Stomski, F. C., Elliott, M. J., Berndt, M. C., Boyd, A. W., Horton, M. A., Cheresh, D. A., Vadas, M. A., and Burns, G. F. (1990) Int. Immunol. 2, 267-277 [Medline] [Order article via Infotrieve]
  42. Wahl, S. M., McCartney-Francis, N., Hunt, D. A., Smith, P. D., Wahl, L. M., and Katona, I. M. (1987) J. Immunol. 139, 1342-1347 [Abstract/Free Full Text]
  43. Illic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., and Aizawa, S. (1995) Nature 377, 539-544 [CrossRef][Medline] [Order article via Infotrieve]
  44. Schaller, M. D., Otey, C. A., Hildebrand, J. D., and Parsons, J. T. (1995) J. Cell Biol. 130, 1181-1187 [Abstract]
  45. Sabe, H., Hata, A., Okada, H., Nakagawa, H., and Hanafusa, H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3984-3988 [Abstract]
  46. Weng, Z., Taylor, J. A., Turner, C. E., Brugge, J. S., and Seidel-Dugan, C. (1993) J. Biol. Chem. 268, 14956-14963 [Abstract/Free Full Text]
  47. Birge, R. B., Fajardo, J. E., Reichman, C., Shoelson, S. E., Songyang, Z., Cantley, L. C., and Hanafusa, H. (1993) Mol. Cell. Biol. 13, 4648-4656 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.